Package insert. Agenerase (amprenavir). Research Triangle Park, NC: GlaxoWellcome, May 2000.
2.
Important drug warning: Potential safety concerns with the large amount of propylene glycol in Agenerase (amprenavir) oral solution. In: “Dear Health Care Professional” letter. Research Triangle Park, NC: GlaxoWellcome, May 2000.
3.
American Academy of Pediatrics, Committee on Drugs. “Inactive” ingredients in pharmaceutical products: Update. Pediatrics1997; 99: 268–78.
4.
ArulanthanKGenelM. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr1978; 93: 515–6.
5.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–45.
